Bart Barlogie

Bart Barlogie, MD

  • PROFESSOR | Medicine, Hematology and Medical Oncology



Bart Barlogie, MD, joined the Icahn School of Medicine as Director of Myeloma Research in 2015.

He had previously headed the Myeloma Institute at the University of Arkansas for Medical Sciences, which he founded in 1989. Under his leadership, a world-renowned program for multiple myeloma research and therapy was established, focusing on "Growth Control in Multiple Myeloma" with the therapeutic goal to achieve cure through the use of myeloablative cytotoxic and immunological treatment strategies.

Dr. Barlogie earned his post-graduate degrees at Heidelberg University and the Max Planck Institute for Medical Research.  Following residency at the Universities of Munich and Muenster, he joined MD Anderson Hospital and Tumor Research Institute as a Fellow under Dr. Emil J Freireich.  Dr. Barlogie's initial laboratory investigation was dedicated to studying tumor cell cycle kinetics and its implications for designing combination chemotherapy.  Dr. Barlogie was one of the first to demonstrate that DNA aneuploidy was a convenient marker for malignancies in most human tumor specimens.  Dr. Barlogie's clinical studies have focused on biological and therapeutic research, including chemotherapy, immunotherapy and hematopoietic stem cell transplantation. 

His notable contributions include:

·         Introducing the first effective salvage regimen for alkylating agent refractory myeloma;

·         Introducing autologous transplants for myeloma;

·         Discovering the activity of thalidomide as the first novel agent in myeloma therapy;

·         Developing the first curative therapy for myeloma through “Total Therapy” protocols that employed all active agents up-front;

·         Introducing genomic profiling into myeloma research for identification of risk-stratified disease subgroups;

·         Introducing novel imaging techniques (MRI and PET-CT) for myeloma staging and response assessment;

·         Developing reproducible prognostic models for myeloma;

·         Identifying myelodysplasia as a consequence of myeloma therapy.

During his tenure in Arkansas, Dr. Barlogie was awarded 20 years of continuous funding from the National Cancer Institute through a P01 program project grant—"Growth Control in Multiple Myeloma"—the first P01 awarded for multiple myeloma.

Heis now focusing his attention on the 15% of patients presenting with genomically defined high-risk MM, by applying metronomically scheduled chemotherapy and targeting mutations.


Dr. Barlogie has published extensively, including more than 580 peer reviewed journal articles including four in the New England Journal of Medicine and 75 book chapters.  

Clinical Focus


MD, Ruprecht-Karl-Universitat

Fellowship, Internal Medicine, MD Anderson Cancer Center (Univ of Texas)

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.